Guardant Health, Inc. (NASDAQ:GH) Receives $37.70 Consensus Price Target from Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.70.

A number of research analysts have issued reports on the stock. Piper Sandler reduced their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. JPMorgan Chase & Co. decreased their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. The Goldman Sachs Group decreased their target price on Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. Finally, Craig Hallum assumed coverage on Guardant Health in a research report on Wednesday, April 24th. They set a “buy” rating and a $28.00 price target on the stock.

Insiders Place Their Bets

In other news, insider Kumud Kalia acquired 2,187 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now directly owns 12,722 shares of the company’s stock, valued at approximately $226,706.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Guardant Health

A number of institutional investors have recently bought and sold shares of GH. Vanguard Group Inc. increased its stake in shares of Guardant Health by 1.4% in the third quarter. Vanguard Group Inc. now owns 10,950,230 shares of the company’s stock worth $324,565,000 after purchasing an additional 146,902 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Guardant Health by 2.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 568,148 shares of the company’s stock worth $16,840,000 after buying an additional 16,111 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Guardant Health during the third quarter valued at about $1,689,000. Rhumbline Advisers lifted its position in shares of Guardant Health by 5.8% in the third quarter. Rhumbline Advisers now owns 159,660 shares of the company’s stock valued at $4,732,000 after acquiring an additional 8,688 shares in the last quarter. Finally, Baillie Gifford & Co. bought a new position in shares of Guardant Health in the fourth quarter worth about $167,137,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Trading Down 1.5 %

NASDAQ GH opened at $18.82 on Friday. The stock has a 50-day moving average of $18.35 and a 200-day moving average of $22.40. The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18. Guardant Health has a 1-year low of $15.81 and a 1-year high of $41.06. The firm has a market cap of $2.29 billion, a PE ratio of -4.40 and a beta of 0.92.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The firm had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. As a group, sell-side analysts forecast that Guardant Health will post -3.49 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.